SoracteLite for Prostate Cancer

Surgery or radiotherapy is the gold standard treatment for low- to intermediate-risk localized prostate cancer patients. Still, the side effects of the treatment and possible patient comorbidities might hamper patients from allowing these kinds of approaches.

In such cases, as stated by the Guidelines on Prostate Cancer issued by medical associations in America and Europe, Focal Therapy may be a therapeutic option to offer to those patients. Among the available Focal Therapies, SoracteLite Transperineal Laser Ablation (TPLA) is a new Focal Laser Ablation (FLA) method that can destroy the lesion without causing the undesired side effects of radical therapies.

SoracteLite for the Treatment of Prostate Cancer

SoracteLite TPLA (Transperineal Laser Ablation), a new Focal Laser Ablation method, consists of the percutaneous insertion of optical fibers via transperineal access under MRI-US Fusion Imaging guidance and the delivery of laser energy for several minutes to heat the tissues until they are destroyed with a sufficient safety margin. The treatment is carried out with needle guiding systems for positioning the applicators in the lesion, allowing the treatment of only the cancerous tissue, thus sparing the remaining healthy prostate.

With just one SoracteLite session, it is possible to obtain the complete ablation of the lesion with sufficient safety margins, allowing the preservation of healthy tissue and the organ’s function.

Which Patients is SoracteLite Indicated For?

• Patients with prostate cancer identified after prostatic biopsy with the fusion of images and targets and systematic samples
• Intermediate progression risk (Gleason Score 3 + 4 or 4 + 3; PSA <15 ng/ml; clinical stage T1-T2a)
• Low risk of progression (Gleason Score 3 + 3) only in patients who wish to leave or who refuse the active surveillance protocol and who refuse validated treatments for the treatment of organ-confined prostate cancer, i.e., radical surgery or radiotherapy

How is the Treatment Carried Out?

Focal Laser Ablation (FLA) is performed with a transperineal approach with the EchoLaser ablation system.

A fusion system MRI-US is necessary to detect and target the tumor. Focal lesions, localized ≥1 cm from the urethra and bladder neck, undergo laser ablation with single or double illumination. The treatment is carried out with the needle guidance system for positioning the applicators in the lesion, allowing them to treat only the cancerous tissue, thus sparing the remaining healthy prostate.

The treatment consists of the percutaneous insertion of optical fibers via transperineal access under MRI-US fusion imaging guidance and the delivery of laser energy for a few minutes to heat the tissues until they are destroyed with a sufficient safety margin.

What are the Goals of Treatment?

• Complete ablation of the tumor with the absence of neoplasia at prostatic biopsy or the presence of Gleason Score 3 + 3 tumor foci, in combination with negative multiparametric MRI.
• Therapeutic failure is defined as the presence of residual Gleason Score neoplasia greater than or equal to 3 + 4 even in the presence of negative multiparametric MRI.